DARK Classics in Chemical Neuroscience: Ibogaine.

@article{Wasko2018DARKCI,
  title={DARK Classics in Chemical Neuroscience: Ibogaine.},
  author={Michael J. Wasko and Paula A. Witt-Enderby and Christopher K. Surratt},
  journal={ACS chemical neuroscience},
  year={2018},
  volume={9 10},
  pages={
          2475-2483
        }
}
The West African iboga plant has been used for centuries by the Bwiti and Mbiri tribes to induce hallucinations during religious ceremonies. Ibogaine, the principal alkaloid responsible for iboga's psychedelic properties, was isolated and sold as an antidepressant in France for decades before its adverse effects precipitated its removal from the market. An ibogaine resurgence in the 1960s was driven by U.S. heroin addicts who claimed that ibogaine cured their opiate addictions. Behavioral… 

Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Addiction States

Oxa-noribogaine maintains and enhances the ability of iboga compounds to effect lasting alteration of addiction-like states while addressing iboga’s cardiac liability, and represents candidates for a new kind of anti-addiction pharmacotherapeutics.

A Non-Hallucinogenic Psychedelic Analog with Therapeutic Potential

This work demonstrates that, through careful chemical design, it is possible to modify a psychedelic compound to produce a safer, non-hallucinogenic variant that has therapeutic potential.

A Single Administration of the Atypical Psychedelic Ibogaine or its Metabolite Noribogaine Induces an Antidepressant-like Effect in Rats.

It is found that ibogaine and noribogaine induced a dose- and time-dependent antidepressant-like effect without significant changes of animal locomotor activity, which suggests a polypharmacological mechanism underpinning the antidepressant- like effects of ibogane and norIBogaine.

The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.

This review will cover recent advances in both the biosynthesis and chemical synthesis of iboga alkaloids as well as their use as next-generation neurotherapeutics and historical context for the discoveries of the past decade is provided.

The Promise of Psychedelic Science.

  • D. E. Olson
  • Psychology, Biology
    ACS pharmacology & translational science
  • 2021
The SAR studies in this issue add to the large body of work by David Nichols, Richard Glennon, and others, investigating how the structures of psychedelics lead to their hallucinogenic effects, and it is now clear that psychedelics can produce a variety of other important biological effects that may contribute to their therapeutic properties.

An Overview of Alkaloids Derived from Tryptophan and Their Potential Antidepressant Action

This research gathered evidence about the activity and obtaining of 37 alkaloids derived from tryptophan, including psilocin, Lysergic acid diethylamide and ibogaine, which are potential candidates for the treatment of depressive disorders and studies suggest that the mechanism of action is in the serotonin receptor agonist and / or inhibition of the monoaminoxidase enzyme.

Pharmacologic Similarities and Differences Among Hallucinogens

  • K. Waters
  • Biology, Psychology
    Journal of clinical pharmacology
  • 2021
The aim of this article is to compare the pharmacologic similarities and differences among substances within the hallucinogen class and their impact on physical and psychiatric effects.

Rapid-Acting Antidepressants.

The preclinical and clinical literature strongly suggests that rapid-acting antidepressants are the current focus of antidepressant drug discovery, and promising clinical findings exist for several compounds including ketamine and other NMDA receptor antagonists, scopolamine, and psilocybin.

Rapid-acting antidepressants.

References

SHOWING 1-10 OF 69 REFERENCES

Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures

It is reported here that ibogaine significantly decreased craving for cocaine and heroin during inpatient detoxification and for short‐term stabilization of drug‐dependent persons as they prepare to enter substance abuse treatment.

Development of Novel Medications for Drug Addiction: The Legacy of an African Shrub

All of the data indicate that 18‐MC should be safer than ibogaine and at least as efficacious as an anti‐addictive medication.

Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review

The purpose of this article was to review data from the literature concerning physicochemical properties, bio-analytical methods, and pharmacology of ibogaine; this article will be focused on the use of this drug as anti-addictive agent.

The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation

The aim of this review is to recapitulate the current knowledge about ibogaine’s effects on the heart and the cardiovascular system, and to assess the cardiac risks associated with the use of this drug in anti- addiction therapy.

Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist

  • B. RothK. Baner R. Rothman
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2002
Salvinorin A is the first naturally occurring nonnitrogenous opioid-receptor subtype-selective agonist for κ opioid receptors and may represent novel psychotherapeutic compounds for diseases manifested by perceptual distortions (e.g., schizophrenia, dementia, and bipolar disorders).

hERG Blockade by Iboga Alkaloids

Results may relate to observations of persistent QT prolongation and cardiac arrhythmia at delayed intervals of days following ibogaine ingestion, and suggest that the iboga alkaloids might provide an informative paradigm for investigation of the structural biology of the hERG channel.
...